NASDAQ · IDYA
IDEAYA Biosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IDYA: Nov 3, 2026
IDEAYA Biosciences, Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.26. The reported EPS for the same quarter last year was $1.33.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.26 | $-1.23 | $-1.30 | 5 |
| Dec 2026 | $-1.13 | $-0.78 | $-1.37 | 5 |
| Mar 2027 | $-1.39 | $-1.31 | $-1.43 | 4 |
| Jun 2027 | $-1.38 | $-1.25 | $-1.46 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel- Zacks · Oct 28, 9:00 AM EDTEarnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to DeclineAcadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 9:00 AM EDTIDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 23, 9:02 AM EDTIDEAYA Reports Promising IDE849 Results In Small Cell Lung Cancer(RTTNews) – IDEAYA Biosciences (IDYA) announced updated Phase 1 results for IDE849, an investigational DLL3-targeted antibody-drug conjugate, showing antitumor activity in relapsed small cell lung cancer (SCLC) and other neuroendocrine carcinomas.
- RTTNews · Oct 19, 8:41 PM EDTIDEAYA Reports Improvements In OS & Tumor Shrinkage For Darovasertib In Uveal Melanoma(RTTNews) – IDEAYA Biosciences Inc. (IDYA), a precision medicine oncology company, on Monday released updated clinical data on three trials evaluating Darovasertib in treating metastatic and primary uveal melanoma (UM).
- Fintel · Oct 16, 4:27 PM EDTWilliam Blair initiates coverage of IDEAYA Biosciences with OutperformFintel reports that on October 16, 2026, William Blair initiated coverage of IDEAYA Biosciences (NASDAQGS:IDYA) (DB:30J) with a Outperform recommendation.IDEAYA Biosciences, Inc., based in the United States, is a biotechnology firm engaged in the discovery and development of targ
- Fintel · Oct 14, 10:21 AM EDTStifel Initiates Coverage of IDEAYA Biosciences with BuyFintel reports that on October 14, 2026, Stifel initiated coverage of IDEAYA Biosciences (NASDAQGS:IDYA) (DB:30J) with a Buy recommendation.Prior to this rating action, the company's stock closed at $34.26 on October 13, 2026. IDEAYA Biosciences, Inc., based in the United States,
- RTTNews · Sep 9, 9:07 AM EDTIDEAYA And Servier Dose First Patient In Global Phase 3 OptimUM-11 Trial For Uveal Melanoma(RTTNews) – IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, and Servier, an independent international pharmaceutical group, announced that the first patient has been dosed in OptimUM-11.
- RTTNews · Aug 31, 7:48 AM EDTIDEAYA Bioscience Advances IDE849 Toward Phase 3 Trial Following FDA Meeting(RTTNews) – IDEAYA Biosciences, Inc. (IDYA) announced a successful FDA Type C meeting that finalized the design of a Phase 3 registrational trial for IDE849, its DLL3-targeting Topo-I antibody drug conjugate (ADC), in extensive stage small cell lung cancer (ES-SCLC).
- RTTNews · Aug 28, 8:36 AM EDTIDEAYA Biosciences Announces Inducement Grants To Newly Hired Employees(RTTNews) – IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company focused on developing targeted cancer therapies, announced inducement grants of non-qualified stock options to purchase an aggregate of 62,800 shares of its common stock for two newly hired employe
- RTTNews · Aug 21, 10:17 AM EDTWeekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks(RTTNews) – This week's global biopharma roundup captured a mix of regulatory approvals, strategic partnerships, acquisitions, and merger activity, alongside clinical trial breakthroughs and halts. Positive readouts across autoimmune myositis, glioma, and melanoma were offset by
- RTTNews · Aug 19, 6:41 AM EDTIDEAYA Biosciences Signs Clinical Collaboration With Genentech On Pancreatic Cancer Study(RTTNews) – Wednesday, IDEAYA Biosciences, Inc. (IDYA) announced a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the efficacy and safety of IDE892 in combination with GDC-7035 in patients with pancreatic ductal adenocarcinoma.
- RTTNews · Jul 28, 4:18 AM EDTIDEAYA Advances IDE892 Into Part 2 Expansion In Phase 1/2 Trial For MTAP-Deleted NSCLC And PDAC(RTTNews) – IDEAYA Biosciences, Inc. (IDYA), a medical oncology company, announced that it has initiated Part 2 monotherapy expansion in its Phase 1/2 clinical trial evaluating IDE892, a methylthioadenosine (MTA) cooperative inhibitor of PRMT5 in MTAP-deleted solid tumours, with
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for IDEAYA Biosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.